Stereotactic Body Radiotherapy for High-Risk Localized Carcinoma of the Prostate (SHARP) Consortium: Analysis of 323 Prospectively Treated Patients
Ritchell van Dams(Brigham and Women's Hospital), Amar U. Kishan(University of California, Los Angeles), Patrick A. Kupelian, Donald B. Fuller(Genesis HealthCare), Vedang Murthy(Homi Bhabha National Institute), Simeng Suy(Georgetown University), Sean P. Collins(Wayne State University), Nicholas G. Nickols(VA Greater Los Angeles Healthcare System), Tahmineh Romero(University of California, Los Angeles), Kevin L. Stephans(Cleveland Clinic), Michael L. Steinberg(University of California, Los Angeles), C. King(University of California, Los Angeles), Nima Aghdam(Georgetown University), Ye Yuan(Peking University), Ning Jiang(University of California, Los Angeles), Ting Jiang(University of California, Los Angeles), Alan J. Katz(Winthrop-University Hospital), Tejshri Telkhade(Tata Memorial Hospital), I.D. Kaplan(Beth Israel Deaconess Medical Center), D.A. Loblaw(American Society of Clinical Oncology)
International Journal of Radiation Oncology*Biology*Physics
October 23, 2020
Cited by 6
Related Papers
The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial
|Nature Medicine|2022|889
The Lancet Commission on prostate cancer: planning for the surge in cases
|The Lancet|2024|694
Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017
|European Urology|2017|644